Late Diabetes Relapse After Sleeve Gastrectomy Compared with Long-Term Remission: Characteristics and Cardiometabolic Outcomes.
Wahiba ElhagWalid El AnsariMoataz BashahIsra ElgenaiedPublished in: Metabolic syndrome and related disorders (2022)
Background: Studies of the relapse of type 2 diabetes mellitus (T2D) after laparoscopic sleeve gastrectomy (LSG) are scarce. We assessed the rate of relapse 5 years after LSG, compared relapsed patients to their baseline and to those with remission, and explored the independent predictors of relapse. Methods: Retrospective analysis of 103 adults who underwent primary LSG at our institution between 2011 and 2015. Data retrieved comprised 23 pre-/postoperative demographic, anthropometric, biochemical, and clinical characteristics. Univariate and multivariate analyses assessed the predictors of relapse. Results: In total, 54% of our patients experienced relapse. Nevertheless, their anthropometric and metabolic profiles significantly improved compared to the values before surgery, reflecting better weight, glycemic, clinical, and biochemical control ( P values ranged from 0.012 to <0.0001). These improvements were mirrored by significant increase in the proportion of relapsed patients meeting the American Diabetes Association treatment goals of hemoglobin A1c (HbA1c), blood pressure, high-density lipoprotein, and triglyceride at 5 years compared with the proportion before surgery ( P = 0.027-0.008). In addition, the anthropometric and metabolic profiles of relapsed patients were not different compared to those of patients with long-term remission ( P = 0.075-0.686), except for a significantly higher prevalence of dyslipidemia and number of diabetes medications among the relapsed group ( P = 0.008 and <0.0001, respectively). Multivariate analysis showed that most of the predictors tested operated in the appropriate direction but fell short of statistical significance. Weight regain at 3 years did not predict relapse at 5 years. Conclusions: Relapse of T2D per se should not undervalue the overall long-term health benefits of LSG. Long-term monitoring of glycemic status after LSG is recommended.
Keyphrases
- end stage renal disease
- ejection fraction
- type diabetes
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- acute myeloid leukemia
- minimally invasive
- prognostic factors
- patients undergoing
- body composition
- high density
- systemic lupus erythematosus
- diffuse large b cell lymphoma
- weight loss
- metabolic syndrome
- risk factors
- risk assessment
- acute coronary syndrome
- rheumatoid arthritis
- body mass index
- cross sectional
- machine learning
- hodgkin lymphoma
- climate change
- bariatric surgery
- artificial intelligence
- hypertensive patients
- human health